Skip to main content
    U

    Upstream Bio, Inc. (UPB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.15
    -0.63 (-22.66%)

    Market Cap: $152.38M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Upstream Bio, Inc. (UPB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Upstream Bio (UPB) to earn -$2.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.47M. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.

    RatingAnalystsShare
    Strong Buy112.5%
    Buy562.5%
    Hold225.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 52.6%.

    Fiscal year ending Dec 31, 2026
    -$2.96
    EPS consensus, revenue $2.47M
    Fiscal year ending Dec 31, 2027
    -$2.63
    EPS consensus, revenue $1.17M
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.96-$3.12 to -$2.817$2.47M$2.20M to $3.00M6
    Dec 31, 2027-$2.63-$3.40 to -$1.776$1.17MN/A5

    Quarterly Estimates

    The EPS consensus falls from -$0.72 for the quarter ending Dec 31, 2026 to -$0.79 for the quarter ending Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.72-$0.93 to -$0.448$431270N/A8
    Mar 31, 2027-$0.79-$1.03 to -$0.614$135670N/A3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 10 upward and 7 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202653
    Fiscal year ending Dec 31, 202733
    Quarter ending Mar 31, 202721

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$2.99.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.96-$2.90-$2.90-$2.90-$2.99N/A
    Fiscal year ending Dec 31, 2027-$2.63-$2.80-$2.80-$2.80-$2.90N/A
    Quarter ending Mar 31, 2027-$0.79-$0.77-$0.77-$0.77-$0.88N/A

    Frequently Asked Questions About UPB

    What is the UPB stock forecast?

    Consensus analyst estimates put Upstream Bio's EPS at -$2.96 for the fiscal year ending Dec 31, 2026, on revenue of $2.47M. The consensus rating from 8 analysts is Buy.

    How do analysts rate UPB stock?

    Of 8 analysts covering Upstream Bio, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from UPB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.96, with estimates from -$3.12 to -$2.81 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.63, with estimates from -$3.40 to -$1.77 from 6 analysts.

    What revenue do analysts expect from Upstream Bio next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.47M, with estimates from $2.20M to $3.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.17M.

    How many analysts cover UPB?

    8 analysts rate Upstream Bio stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.